About the Company
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on HALOZYME THERAPEUTICS, INC.
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ...
Halozyme Therapeutics Inc (HALO) reports a 41% revenue increase, raises 2025 guidance, and advances share repurchase program ...
What 7 Analyst Ratings Have To Say About Halozyme Therapeutics
Analysts have set 12-month price targets for Halozyme Therapeutics, revealing an average target of $73.71, a high estimate of $91.00, and a low estimate of $60.00. Surpassing the previous average ...
1HALO : Earnings Outlook For Halozyme Therapeutics
Analysts expect Halozyme Therapeutics to report an earnings per share (EPS) of $1.20. Anticipation surrounds Halozyme Therapeutics's announcement, with investors hoping to hear about both surpassing ...
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled ...
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ...
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C.
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets made a ...
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ: HALO) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communications ...
First Week of June 2025 Options Trading For Halozyme Therapeutics (HALO ...
Investors in Halozyme Therapeutics Inc (Symbol: HALO) saw new options begin trading this week, for the June 2025 expiration. One of the key inputs that goes into the price an option buyer is ...
Halozyme Therapeutics, Inc. Q4 Profit Increases, Beats Estimates
Excluding items, Halozyme Therapeutics, Inc. reported adjusted earnings of $1.26 per share for the period. Analysts on average had expected the company to earn $1.16 per share.
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and ... - KHON2
News provided by Halozyme Therapeutics, Inc. Jan 08, 2025, 7:00 AM ET Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.78 Consensus ...
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and ...
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million ...
The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offering SAN DIEGO, Aug. 15, 2022 /PRNewswire/ -- Halozyme Therapeutics ...
Similar Companies
Loading the latest forecasts...